Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis

Abstract Background Obsessive-compulsive disorder (OCD) is among the most disabling neuropsychiatric conditions characterized by the presence of repetitive intrusive thoughts, impulses, or images (obsessions) and/or ritualized mental or physical acts (compulsions). Serotonergic medications, particul...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fatemeh Hadi, Shayan Kashefinejad, Leila Kamalzadeh, Saba Hoobehfekr, Mohammadreza Shalbafan
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Acceso en línea:https://doaj.org/article/5d4be219e9d64309804d7a0d2d597db3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:5d4be219e9d64309804d7a0d2d597db3
record_format dspace
spelling oai:doaj.org-article:5d4be219e9d64309804d7a0d2d597db32021-11-08T10:45:47ZGlutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis10.1186/s40360-021-00534-62050-6511https://doaj.org/article/5d4be219e9d64309804d7a0d2d597db32021-11-01T00:00:00Zhttps://doi.org/10.1186/s40360-021-00534-6https://doaj.org/toc/2050-6511Abstract Background Obsessive-compulsive disorder (OCD) is among the most disabling neuropsychiatric conditions characterized by the presence of repetitive intrusive thoughts, impulses, or images (obsessions) and/or ritualized mental or physical acts (compulsions). Serotonergic medications, particularly Selective Serotonin Reuptake Inhibitors (SSRIs), are the first-line treatments for patients with OCD. Recently, dysregulation of glutamatergic system has been proposed to be involved in the etiology of OCD. We designed this systematic review and meta-analysis to evaluate clinical efficacy of glutamatergic medications in patients with OCD, according to the guidelines of Cochrane collaboration. Method We searched Medline, Scopus, and Cochrane library without applying any language filter. Two of the authors independently reviewed search results for irrelevant and duplicate studies and extracted data and assessed methodological quality of the studies. We transformed data into a common rubric and calculated a weighted treatment effect across studies using Review Manager. Results We found 476 references in 3 databases, and after exclusion of irrelevant and duplicate studies, 17 studies with total number of 759 patients with OCD were included. In the present review we found evidence for several drugs such as memantine, N-acetylcysteine (NAC), Minocycline, L-carnosine and riluzole. Glutamaterigic drug plus SSRIs were superior to SSRI+ Placebo with regard to Y-BOCS scale [standardized mean difference (SMD = − 3.81 95% CI = − 4.4, − 3.23). Conclusion Augmentation of glutamatergic medications with SSRIs are beneficial in obsessive-compulsive patients, no harmful significant differences in any safety outcome were found between the groups.Fatemeh HadiShayan KashefinejadLeila KamalzadehSaba HoobehfekrMohammadreza ShalbafanBMCarticleGlutamateRiluzoleMemantineMinocyclineObsessive-compulsive disorderSystematic reviewTherapeutics. PharmacologyRM1-950Toxicology. PoisonsRA1190-1270ENBMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-11 (2021)
institution DOAJ
collection DOAJ
language EN
topic Glutamate
Riluzole
Memantine
Minocycline
Obsessive-compulsive disorder
Systematic review
Therapeutics. Pharmacology
RM1-950
Toxicology. Poisons
RA1190-1270
spellingShingle Glutamate
Riluzole
Memantine
Minocycline
Obsessive-compulsive disorder
Systematic review
Therapeutics. Pharmacology
RM1-950
Toxicology. Poisons
RA1190-1270
Fatemeh Hadi
Shayan Kashefinejad
Leila Kamalzadeh
Saba Hoobehfekr
Mohammadreza Shalbafan
Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis
description Abstract Background Obsessive-compulsive disorder (OCD) is among the most disabling neuropsychiatric conditions characterized by the presence of repetitive intrusive thoughts, impulses, or images (obsessions) and/or ritualized mental or physical acts (compulsions). Serotonergic medications, particularly Selective Serotonin Reuptake Inhibitors (SSRIs), are the first-line treatments for patients with OCD. Recently, dysregulation of glutamatergic system has been proposed to be involved in the etiology of OCD. We designed this systematic review and meta-analysis to evaluate clinical efficacy of glutamatergic medications in patients with OCD, according to the guidelines of Cochrane collaboration. Method We searched Medline, Scopus, and Cochrane library without applying any language filter. Two of the authors independently reviewed search results for irrelevant and duplicate studies and extracted data and assessed methodological quality of the studies. We transformed data into a common rubric and calculated a weighted treatment effect across studies using Review Manager. Results We found 476 references in 3 databases, and after exclusion of irrelevant and duplicate studies, 17 studies with total number of 759 patients with OCD were included. In the present review we found evidence for several drugs such as memantine, N-acetylcysteine (NAC), Minocycline, L-carnosine and riluzole. Glutamaterigic drug plus SSRIs were superior to SSRI+ Placebo with regard to Y-BOCS scale [standardized mean difference (SMD = − 3.81 95% CI = − 4.4, − 3.23). Conclusion Augmentation of glutamatergic medications with SSRIs are beneficial in obsessive-compulsive patients, no harmful significant differences in any safety outcome were found between the groups.
format article
author Fatemeh Hadi
Shayan Kashefinejad
Leila Kamalzadeh
Saba Hoobehfekr
Mohammadreza Shalbafan
author_facet Fatemeh Hadi
Shayan Kashefinejad
Leila Kamalzadeh
Saba Hoobehfekr
Mohammadreza Shalbafan
author_sort Fatemeh Hadi
title Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis
title_short Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis
title_full Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis
title_fullStr Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis
title_full_unstemmed Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis
title_sort glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis
publisher BMC
publishDate 2021
url https://doaj.org/article/5d4be219e9d64309804d7a0d2d597db3
work_keys_str_mv AT fatemehhadi glutamatergicmedicationsasadjunctivetherapyformoderatetosevereobsessivecompulsivedisorderinadultsasystematicreviewandmetaanalysis
AT shayankashefinejad glutamatergicmedicationsasadjunctivetherapyformoderatetosevereobsessivecompulsivedisorderinadultsasystematicreviewandmetaanalysis
AT leilakamalzadeh glutamatergicmedicationsasadjunctivetherapyformoderatetosevereobsessivecompulsivedisorderinadultsasystematicreviewandmetaanalysis
AT sabahoobehfekr glutamatergicmedicationsasadjunctivetherapyformoderatetosevereobsessivecompulsivedisorderinadultsasystematicreviewandmetaanalysis
AT mohammadrezashalbafan glutamatergicmedicationsasadjunctivetherapyformoderatetosevereobsessivecompulsivedisorderinadultsasystematicreviewandmetaanalysis
_version_ 1718442620345122816